Mesonephric Adenocarcinoma in a Young Male Patient.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-02-01 DOI:10.21873/anticanres.17449

Daniela Guevara, Nara Shin, Alexandra Boiko, Ivan Valiev, Ahmed G Elsaeed, Juan Miguel Mosquera, Majd Al Assaad, Jyothi Manohar, Michael Sigouros, Alisa Zaichikova, Victoria Fomchenkova, Leysan Yunusova, Sofia Smirnova, Olivier Elemento, Jones Nauseef, Cora N Sternberg

{"title":"Mesonephric Adenocarcinoma in a Young Male Patient.","authors":"Daniela Guevara, Nara Shin, Alexandra Boiko, Ivan Valiev, Ahmed G Elsaeed, Juan Miguel Mosquera, Majd Al Assaad, Jyothi Manohar, Michael Sigouros, Alisa Zaichikova, Victoria Fomchenkova, Leysan Yunusova, Sofia Smirnova, Olivier Elemento, Jones Nauseef, Cora N Sternberg","doi":"10.21873/anticanres.17449","DOIUrl":null,"url":null,"abstract":"Background/aim: Mesonephric adenocarcinoma in males is an exceptionally rare malignancy arising from mesonephric remnants. Accurate diagnosis requires thorough histopathological and molecular analysis.Case report: A 33-year-old male presented with right lower quadrant pain, and imaging revealed a pelvic mass compressing adjacent structures. Biopsy confirmed mesonephric adenocarcinoma. Genetic profiling revealed mutations in tuberous sclerosis complex 2 (TSC2) and phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha (PIK3CA), offering potential for targeted therapy.Conclusion: This case highlights the diagnostic and therapeutic challenges of mesonephric adenocarcinoma in males. Molecular profiling provided insights into tumor biology and potential targeted treatments. Multidisciplinary collaboration and surveillance remain essential for managing rare malignancies effectively.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 2","pages":"619-623"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17449","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Mesonephric adenocarcinoma in males is an exceptionally rare malignancy arising from mesonephric remnants. Accurate diagnosis requires thorough histopathological and molecular analysis.

Case report: A 33-year-old male presented with right lower quadrant pain, and imaging revealed a pelvic mass compressing adjacent structures. Biopsy confirmed mesonephric adenocarcinoma. Genetic profiling revealed mutations in tuberous sclerosis complex 2 (TSC2) and phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha (PIK3CA), offering potential for targeted therapy.

Conclusion: This case highlights the diagnostic and therapeutic challenges of mesonephric adenocarcinoma in males. Molecular profiling provided insights into tumor biology and potential targeted treatments. Multidisciplinary collaboration and surveillance remain essential for managing rare malignancies effectively.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.